Skip to main content

Diabetic Foot Infection

7
Pipeline Programs
6
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
5
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

MicuRx Pharmaceuticals
MicuRx PharmaceuticalsCA - Foster City
1 program
1
contezolid acefosamilPhase 31 trial
Active Trials
NCT05369052Recruiting865Est. Jun 2026
Microbion
MicrobionMT - Bozeman
2 programs
1
1
Topical PravibismanePhase 21 trial
MBN-101Phase 11 trial
Active Trials
NCT02723539Completed52Est. Jul 2019
NCT05174806Completed47Est. Jan 2024
Lakewood-Amedex
Lakewood-AmedexFL - University Park
1 program
1
5% Nu-3 gelPhase 21 trial
Active Trials
NCT06020235Not Yet Recruiting60Est. Aug 2026
TechnoPhage
TechnoPhagePortugal - Lisbon
1 program
1
TP-102Phase 21 trial
Active Trials
NCT05948592Completed76Est. Dec 2025
Biomed
BiomedAustralia - Sydney
1 program
1
[124I]FIAUPhase 21 trial
Active Trials
NCT01764919Terminated4Est. Feb 2014
BioMed Valley Discoveries
1 program
1
[124I]FIAUPhase 2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MicuRx Pharmaceuticalscontezolid acefosamil
Lakewood-Amedex5% Nu-3 gel
TechnoPhageTP-102
MicrobionTopical Pravibismane
Biomed[124I]FIAU
MicrobionMBN-101

Clinical Trials (6)

Total enrollment: 1,104 patients across 6 trials

NCT05369052MicuRx Pharmaceuticalscontezolid acefosamil

Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

Start: May 2022Est. completion: Jun 2026865 patients
Phase 3Recruiting
NCT06020235Lakewood-Amedex5% Nu-3 gel

Nu-3 Gel for Infected Diabetic Foot Ulcers

Start: Dec 2025Est. completion: Aug 202660 patients
Phase 2Not Yet Recruiting
NCT05948592TechnoPhageTP-102

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

Start: Nov 2023Est. completion: Dec 202576 patients
Phase 2Completed
NCT05174806MicrobionTopical Pravibismane

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

Start: Jun 2022Est. completion: Jan 202447 patients
Phase 2Completed
NCT01764919Biomed[124I]FIAU

[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection

Start: Apr 2013Est. completion: Feb 20144 patients
Phase 2Terminated
NCT02723539MicrobionMBN-101

A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

Start: Mar 2017Est. completion: Jul 201952 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,104 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.